505(b)(2) development lead must resolve whether to resubmit, meet, or pause

Situation

FDA Response and Labeling work in a rare-disease team designing a pediatric plan now turns on to resubmit, meet, or because a boxed-warning proposal from the review division put complete-response-letter deficiency list in play. 505(b)(2) development lead should say what complete-response-letter deficiency list proves.

Decision

505(b)(2) development lead in a rare-disease team designing a pediatric plan must choose To resubmit, meet, / Pause the program using complete-response-letter deficiency list after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize To resubmit, meet, now; complete-response-letter deficiency list already has the discriminator after a boxed-warning proposal from the review division.
• Keep Pause the program in force until complete-response-letter deficiency list is completed after a boxed-warning proposal from the review division for 505(b)(2) development lead.
• Treat complete-response-letter deficiency list as To resubmit, meet, because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page to resubmit, meet, or turns on in complete-response-letter deficiency list.

Analysis required

• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a boxed-warning proposal from the review division and write the one fact that would move to resubmit, meet, or for 505(b)(2) development lead.

Recommendation

Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a boxed-warning proposal from the review division). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a rare-disease team designing a pediatric plan does not have.